Dr. Randi Jenssen Hagerman, MD

Dr. Hagerman practices at Mind Institute Clinic - HOPD in Sacramento, California.

Dr. Hagerman's NPI, 1659356020, was assigned on December 8, 2005. Dr. Hagerman graduated from Stanford University School Of Medicine in 1975. Dr. Hagerman holds California license G32435.

Dr. Hagerman's primary practice is Mind Institute Clinic - HOPD, at 2825 50th St, Sacramento, CA 95817.

Dr. Hagerman's primary practice is Mind Institute Clinic - HOPD in Sacramento, California. Dr. Hagerman is also affiliated with UC Davis Medical Center. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Hagerman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hagerman practices, 3 sites in all. Vendor and product names are available with a free account.

Developmental - behavioral pediatrics is Dr. Hagerman's primary specialty in the NPI Registry, under taxonomy code 2080P0006X. Dr. Hagerman is board certified in developmental-behavioral pediatrics by the American Board of Pediatrics. Dmand AI has Dr. Hagerman's licenses on file in 3 states: California, Colorado and Wyoming.

Dmand AI lists intellectual and developmental disabilities among the conditions Dr. Hagerman treats.

CMS data shows 15 Medicare services from Dr. Hagerman across 1 procedure code in 2023, all of them office visits, for 15 Medicare patients. Medicare paid $1,370 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 15 Medicare patients who saw Dr. Hagerman in 2024. The largest group is 85 and over, with 0 patients. Their average risk score is 0.65, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Hagerman's median patient age at 16, with 27% women.

In 2024, Dr. Hagerman wrote 232 Medicare Part D claims for 16 patients. 100% of them were for generic drugs. CMS names the drug for 196 of them, across 9 drugs with 11 or more claims each, at $11,055 in total drug cost. In 2023, CMS named 226 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Hagerman for performance year 2024, reported as part of a group. Dr. Hagerman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hagerman as offering telehealth.

Dmand AI links 423 papers to Dr. Hagerman, published from 2003 to 2025. 2020 was the busiest year, with 24. The most frequent topics are Fragile X Syndrome, Fragile X Mental Retardation Protein and Tremor. Dr. Hagerman has published most often in Am J Med Genet A. Dr. Hagerman's most frequent co-authors are Reymundo Lozano, MD, Elizabeth M. Berry-Kravis, MD and John Michael Olichney, MD.

Dmand AI links Dr. Hagerman to 9 clinical trials, 3 of them phase 2 studies. Conditions studied include Fragile X Syndrome, Sex Chromosome Disorders and Fragile X Tremor Ataxia Syndrome. University of California, Davis sponsors the most, 5.

CMS Open Payments shows 32 general payments to Dr. Hagerman from 2 drug and device companies from 2019 to 2025. Travel and lodging make up the largest share, 73% of the total. Shionogi Inc paid the most, $1,289.

Dr. Hagerman graduated from Stanford University School Of Medicine in 1975. Dr. Hagerman is a member of APA.

Dr. Hagerman is in network with 7 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.